Therapeutic drug monitoring of antimicrobials

被引：17

作者：

Balakrishnan, Indran ^{[1
,2
]}

Shorten, Robert J. ^{[2
,3
]}

机构：

[1] Royal Free London NHS Fdn Trust, Dept Med Microbiol, London, England

[2] UCL, Ctr Clin Microbiol, Royal Free Campus, London, England

[3] Manchester Royal Infirm, Publ Hlth Lab Manchester, Oxford Rd, Manchester M13 9WL, Lancs, England

来源：

ANNALS OF CLINICAL BIOCHEMISTRY | 2016年 / 53卷 / 03期

关键词：

Antimicrobial therapy; therapeutic drug monitoring; ESCHERICHIA-COLI; DISSEMINATED CANDIDIASIS; ORAL POSACONAZOLE; BRITISH SOCIETY; AMPHOTERICIN-B; PHARMACOKINETICS; VORICONAZOLE; GENTAMICIN; VANCOMYCIN; SAFETY;

D O I：

10.1177/0004563215618981

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

As pathology services become more centralized and automated, the measurement of therapeutic antimicrobial drugs concentrations is increasingly performed in clinical biochemistry or blood science' laboratories. This review outlines key groups of antimicrobial agents: aminoglycosides, glycopeptides, antifungal agents and antituberculosis agents, their role in managing infectious diseases, and the reasons why serum concentration measurement is important.

引用

页码：333 / 346

页数：14

共 53 条

[31] Therapeutic drug monitoring in the treatment of tuberculosis patients [J].

Magis-Escurra, Cecile ;

van den Boogaard, Jossy ;

IJdema, Dirk ;

Boeree, Martin ;

Aarnoutse, Rob .

PULMONARY PHARMACOLOGY & THERAPEUTICS, 2012, 25 (01) :83-86

[32] TEICOPLANIN - RENAL TOLERANCE AND PHARMACOKINETICS IN RATS [J].

MARRE, R ;

SCHULZ, E ;

GRAEFE, H ;

SACK, K .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 20 (05) :697-704

[33]

MELANCON P, 1992, J BACTERIOL, V174, P7896

[34] Aminoglycosides: Activity and resistance [J].

Mingeot-Leclercq, MP ;

Glupczynski, Y ;

Tulkens, PM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :727-737

[35] Aminoglycosides: Nephrotoxicity [J].

Mingeot-Leclercq, MP ;

Tulkens, PM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1003-1012

[36] ANTIBACTERIAL ACTIVITIES AND MODES OF ACTION OF VANCOMYCIN AND RELATED GLYCOPEPTIDES [J].

NAGARAJAN, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :605-609

[37] The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial [J].

Park, Wan Beom ;

Kim, Nak-Hyun ;

Kim, Kye-Hyung ;

Lee, Seung Hwan ;

Nam, Won-Seok ;

Yoon, Seo Hyun ;

Song, Kyoung-Ho ;

Choe, Pyoeng Gyun ;

Kim, Nam Joong ;

Jang, In-Jin ;

Oh, Myoung-don ;

Yu, Kyung-Sang .

CLINICAL INFECTIOUS DISEASES, 2012, 55 (08) :1080-1087

[38] Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes [J].

Pascual, Andres ;

Calandra, Thierry ;

Bolay, Saskia ;

Buclin, Thierry ;

Bille, Jacques ;

Marchetti, Oscar .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (02) :201-211

[39] Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi:: Report from SENTRY Antimicrobial Surveillance Program, 2000 [J].

Pfaller, MA ;

Messer, SA ;

Hollis, RJ ;

Jones, RN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1032-1037

[40] Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study [J].

Prahl, Julie B. ;

Johansen, Isik S. ;

Cohen, Arieh S. ;

Frimodt-Moller, Niels ;

Andersen, Ase B. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (10) :2841-2847

← 1 2 3 4 5 6 →